The association of mutant Kras with pancreatic cancer was established decades ago (Almoguera et al., 1988; Smit et al., 1988); the most common mutation is one amino-acid substitution in position 12 of the Kras protein, leading to a glycine (G) to aspartic acid (D) substitution, although other variants, such as G to V are also common (for review see Pylayeva-Gupta et al., 2011). The gene discussed is KRAS; the disease is pancreatic neoplasm.